Companies pursue souped-up IL-2 candidates, undeterred by Nektar’s setback.
Undeterred by bempegaldesleukin’s demise, the industry is forging ahead with a diverse pipeline of designer IL-2–based agents — more than a dozen of which are now in the clinic — as developers hope to overcome the challenges that have kept the cytokine from its immuno-oncology promise (Table 1). Many companies are eyeing applications in autoimmunity, too. “There are a lot of good strategies that are out there,” says Marc Ernstoff, chief of the ImmunoOncology Branch at the US National Cancer Institute. “Each of the engineered IL-2–like drugs is unique — and I think each will have to be tested.”
This is a preview of subscription content
Access options
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
$99.00
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
About this article
Cite this article
Dolgin, E. IL-2 upgrades show promise at ASCO.
Nat Biotechnol (2022). https://doi.org/10.1038/s41587-022-01390-3
-
Published:
-
DOI: https://doi.org/10.1038/s41587-022-01390-3
